Theraclion announced revenue results for the full year of 2014. For the period, the company's sales of EUR 800,000 against EUR 15,000 a year ago. 97% of 2014 revenues were comprised of sales to three major customers: the American Hospital of Paris.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.316 EUR | -4.53% | -3.66% | -18.56% |
06-24 | Sonovein FDA Pivotal Study Treatments Completed: Theraclion Reaches Key Milestone on Schedule | CI |
06-07 | Theraclion: scientific publication hailed by stock market | CF |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-18.56% | 15.78M | |
+4.57% | 212B | |
+8.61% | 186B | |
+26.34% | 151B | |
+33.90% | 114B | |
+2.17% | 65.57B | |
+14.50% | 52.61B | |
-3.30% | 46.8B | |
-3.98% | 38.95B | |
+6.66% | 37.64B |
- Stock Market
- Equities
- ALTHE Stock
- News Theraclion
- Theraclion Announces Revenue Results for the Full Year of 2014